TransCode Therapeutics announced that it has received notice from the NASDAQ Stock Market that the Company has regained compliance with all applicable Nasdaq listing standards. As a result, the Company’s stock will remain listed and traded on the Nasdaq Stock Market. The Company’s hearing before the Nasdaq Hearing Panel scheduled for June 25, 2024, has been cancelled. As previously disclosed, the Company remains subject to a mandatory Nasdaq panel monitor through January 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
- Transcode Therapeutics reports data from FIH study of TTX-MC138
- Transcode Therapeutics board issues letter to shareholders
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors